ABNCoV2
COVID-19
Phase 3Active (Out-licensed)
Key Facts
About AdaptVac
AdaptVac is a clinical-stage vaccine developer with a validated, proprietary cVLP display platform. The company has advanced its platform through a Phase 3 COVID-19 vaccine (ABNCoV2) and has a pipeline including a HER2+ breast cancer vaccine in Phase 1 and a Nipah virus vaccine in pre-clinical development. With strong academic roots from the University of Copenhagen and significant non-dilutive funding, AdaptVac is positioned to create durable vaccines for both commercial and equitable access markets. Its business model is primarily out-licensing of vaccine candidates developed on its platform.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |